{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:48:30Z","timestamp":1788961710369,"version":"build-2803163510"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Evidences for anticoagulation strategies in cirrhotic with portal vein thrombosis (PVT) are still insufficient. This study aims to comprehensively compare the therapeutic effects of different therapeutic therapeutic measures in individuals suffering from cirrhosis with PVT, with the ultimate goal of providing evidence-based recommendations for thrombolytic therapy in this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Starting from 20 October 2023, a comprehensive search about therapeutic strategies for portal vein thrombosis in cirrhosis was conducted on PubMed, EMBASE, and Cochrane Library.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>19 studies were eventually incorporated into this study. Comparison with control in network meta-analysis, direct oral anticoagulants (DOACs) (RR = 2.15, 95%CI: 1.33, 3.48), LMWH (RR = 1.41, 95%CI: 1.01, 1.99), TIPS (RR = 5.68, 95%CI: 2.63, 12.24), warfarin (RR = 2.16, 95%CI: 1.46, 3.21), EBL <jats:italic>plus<\/jats:italic> propranolol (RR = 2.80, 95%CI: 1.18, 6.60), LMWH-DOACs sequential (RR = 7.92, 95%CI: 2.85, 21.99) and LMWH-warfarin sequential (RR = 2.26, 95%CI: 1.16, 4.42) significantly improved the incidence of complete recanalization. The anticoagulation drugs were ranked based on their SUCRA values, with the LMWH-DOACs sequential (92.7%), TIPS <jats:italic>plus<\/jats:italic> warfarin (91.3%), and TIPS (80.3%) emerging as the top three effective treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this study, active anticoagulants were recommended for cirrhosis with PVT. The TIPS <jats:italic>plus<\/jats:italic> warfarin, LMWH-DOACs sequential, and TIPS improved the complete recanalization rate most effectively, and the EBL <jats:italic>plus<\/jats:italic> propranolol, heparin <jats:italic>plus<\/jats:italic> DOACs <jats:italic>plus<\/jats:italic> warfarin, and DOACs were highly recommended for increasing the incidence of partial recanalization. Warfarin and TIPS were recommended for reducing the frequency of bleeding events, while LMWH <jats:italic>plus<\/jats:italic> warfarin and DOACs proved to be most effective in decreasing the rate of major bleeding events. Warfarin, heparin <jats:italic>plus<\/jats:italic> DOACs <jats:italic>plus<\/jats:italic> warfarin, and DOACs demonstrated the most significant reduction in mortality rates, highlighting its potential as an effective intervention. TIPS <jats:italic>plus<\/jats:italic> warfarin, LMWH-DOACs sequential, and TIPS were recommended for reducing the occurrence of PVT expansion. Heparin <jats:italic>plus<\/jats:italic> DOACs <jats:italic>plus<\/jats:italic> warfarin was recommended for reducing the occurrence of hepatic encephalopathy, and protocols that involve TIPS were generally associated with a higher risk of hepatic encephalopathy. However, a longer follow-up period is necessary to comprehensively evaluate the efficacy of active anticoagulants therapy in patients with PVT in cirrhosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1462338","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T07:06:39Z","timestamp":1736147199000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Administration of anticoagulation strategies for portal vein thrombosis in cirrhosis: network meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Hui-Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Qiang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Feng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1097\/MEG.0000000000001846","article-title":"Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis","volume":"32","author":"Ai","year":"2020","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1016\/s1590-8658(13)60485-5","article-title":"P.11.20 clinical outcome of partial portal vein thrombosis in cirrhotic patients: to observe or to treat?","volume":"45","author":"Caracciolo","year":"2013","journal-title":"Dig. Liver Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/MEG.0000000000000482","article-title":"Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis","volume":"28","author":"Chen","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3350\/cmh.2014.20.4.384","article-title":"Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis","volume":"20","author":"Chung","year":"2014","journal-title":"Clin. Mol. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"374","DOI":"10.15403\/jgld-3392","article-title":"Anticoagulation therapy for portal vein thrombosis in patients with cirrhosis in a tertiary center experience","volume":"30","author":"Florescu","year":"2021","journal-title":"J. Gastrointestin Liver Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11739-023-03206-x","article-title":"Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial","volume":"18","author":"Gao","year":"2023","journal-title":"Intern Emerg. Med."},{"key":"B7","first-page":"1261A","article-title":"Clinical outcome of portal vein thrombosis (PVT) in cirrhotic patients: observe or treat?","volume":"54","author":"Garcovich","year":"2011","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.20524\/aog.2020.0544","article-title":"Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis: a systematic review and meta-analysis","volume":"34","author":"Ghazaleh","year":"2021","journal-title":"Ann. Gastroenterol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1111\/jgh.16263","article-title":"Natural history of portal vein thrombosis in cirrhosis: a systematic review with meta-analysis","volume":"38","author":"Giri","year":"2023","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"968988","DOI":"10.3389\/fphar.2022.968988","article-title":"Transjugular intrahepatic portosystemic shunt for the prevention of rebleeding in patients with cirrhosis and portal vein thrombosis: systematic review and meta-analysis","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"107142","DOI":"10.1016\/j.vph.2023.107142","article-title":"Retraction notice to \u201cRandomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis\u201d [Vascular Pharmacology 113 (2019) 86-91]","volume":"153","author":"Hanafy","year":"2023","journal-title":"Vasc. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12876-019-1140-8","article-title":"Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients","volume":"19","author":"Hayashi","year":"2019","journal-title":"BMC Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3760\/cma.j.cn501113-20200616-00326","article-title":"Impact of portal vein thrombosis on the efficacy of endoscopic treatment in preventing re-bleeding from ruptured gastroesophageal varices in hepatitis B-related liver cirrhosis","volume":"28","author":"Huang","year":"2020","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S549","DOI":"10.14309\/01.ajg.0000706388.88885.06","article-title":"S1085 direct oral anticoagulants and warfarin in patients with cirrhosis and portal vein thrombosis: a comparison of outcomes","volume":"115","author":"Joseph","year":"2020","journal-title":"Official J. Am. Coll. Gastroenterology | ACG."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.cgh.2017.10.016","article-title":"Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis","volume":"16","author":"La Mura","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1055\/s-0043-1770100","article-title":"Risk of bleeding in liver cirrhosis receiving direct oral anticoagulants: a systematic review and meta-analysis","volume":"123","author":"Li","year":"2023","journal-title":"Thromb. Haemost."},{"key":"B18","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1148\/radiol.15141252","article-title":"Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding","volume":"276","author":"Luo","year":"2015","journal-title":"Radiology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.14309\/ajg.0000000000001194","article-title":"Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis: a prospective observational study","volume":"116","author":"Lv","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1136\/gutjnl-2017-314634","article-title":"Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial","volume":"67","author":"Lv","year":"2018","journal-title":"Gut"},{"key":"B22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.23736\/S2724-5985.21.02861-8","article-title":"Treatment of portal vein thrombosis in cirrhosis: a multicenter real life c\u03bfhort study","volume":"69","author":"Mantaka","year":"2023","journal-title":"Minerva Gastroenterol. (Torino)."},{"key":"B23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.20524\/aog.2020.0503","article-title":"Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: systematic review and meta-analysis","volume":"33","author":"Mohan","year":"2020","journal-title":"Ann. Gastroenterol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1007\/s10620-023-07930-4","article-title":"Safety and efficacy of transjugular intrahepatic portosystemic shunt for non-tumoral cirrhotic portal vein thrombosis not responding to anticoagulation therapy","volume":"68","author":"Mukund","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/hepr.12895","article-title":"Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis","volume":"48","author":"Nagaoki","year":"2018","journal-title":"Hepatol. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1007\/s10620-020-06695-4","article-title":"Safety, efficacy, and long-term outcomes of anticoagulation in cirrhotic portal vein thrombosis","volume":"66","author":"Naymagon","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1111\/liv.14121","article-title":"Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: a prospective study","volume":"39","author":"Noronha Ferreira","year":"","journal-title":"Liver Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1007\/s10620-019-05572-z","article-title":"Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis","volume":"64","author":"Noronha Ferreira","year":"","journal-title":"Dig. Dis. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejim.2022.05.032","article-title":"Epidemiology of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis","volume":"104","author":"Pan","year":"2022","journal-title":"Eur. J. Intern Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41395-018-0421-0","article-title":"Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis","volume":"114","author":"Pettinari","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/apt.15044","article-title":"Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis","volume":"49","author":"Rodrigues","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/MEG.0000000000001237","article-title":"A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis","volume":"31","author":"Rodriguez-Castro","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s00508-018-1351-y","article-title":"Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function","volume":"130","author":"Scheiner","year":"2018","journal-title":"Wien Klin. Wochenschr"},{"key":"B34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jhep.2021.04.029","article-title":"Current knowledge and management of portal vein thrombosis in cirrhosis","volume":"75","author":"Senzolo","year":"2021","journal-title":"J. Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/j.1478-3231.2012.02785.x","article-title":"Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis","volume":"32","author":"Senzolo","year":"2012","journal-title":"Liver Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/hep.31264","article-title":"Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation","volume":"73","author":"Serper","year":"2021","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.14309\/ajg.0000000000000486","article-title":"ACG clinical guideline: disorders of the hepatic and mesenteric circulation","volume":"115","author":"Simonetto","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Bmj"},{"key":"B39","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B40","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.3748\/wjg.v25.i45.6668","article-title":"Prognostic value of risk scoring systems for cirrhotic patients with variceal bleeding","volume":"25","author":"Tantai","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/hep4.1513","article-title":"Direct oral anticoagulants in patients with atrial fibrillation and advanced liver disease: an exploratory meta-analysis","volume":"4","author":"Violi","year":"2020","journal-title":"Hepatol. Commun."},{"key":"B42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.15420\/aer.2017.50.1","article-title":"The significance of drug-drug and drug-food interactions of oral anticoagulation","volume":"7","author":"Vranckx","year":"2018","journal-title":"Arrhythm. Electrophysiol. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12325-020-01550-4","article-title":"Anticoagulation favors thrombus recanalization and survival in patients with liver cirrhosis and portal vein thrombosis: results of a meta-analysis","volume":"38","author":"Wang","year":"2021","journal-title":"Adv. Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1148\/radiol.2015150369","article-title":"Is post-TIPS anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? A randomized controlled trial","volume":"279","author":"Wang","year":"2016","journal-title":"Radiology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1080\/00365521.2022.2094724","article-title":"Comparison of transjugular intrahepatic portosystemic with endoscopic treatment plus anticoagulation for esophageal variceal bleeding and portal vein thrombosis in liver cirrhosis","volume":"57","author":"Wu","year":"2022","journal-title":"Scand. J. Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.12998\/wjcc.v9.i19.5179","article-title":"Systematic review and meta-analysis of trans-jugular intrahepatic portosystemic shunt for cirrhotic patients with portal vein thrombosis","volume":"9","author":"Zhang","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"B47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12959-023-00454-x","article-title":"Safety, efficacy and prognosis of anticoagulant therapy for portal vein thrombosis in cirrhosis: a retrospective cohort study","volume":"21","author":"Zhang","year":"2023","journal-title":"Thromb. J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"7372868","DOI":"10.1155\/2020\/7372868","article-title":"The prognosis analysis of liver cirrhosis with acute variceal bleeding and validation of current prognostic models: a large scale retrospective cohort study","volume":"2020","author":"Zhao","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e00228","DOI":"10.14309\/ctg.0000000000000228","article-title":"Efficacy and safety of nadroparin calcium-warfarin sequential anticoagulation in portal vein thrombosis in cirrhotic patients: a randomized controlled trial","volume":"11","author":"Zhou","year":"2020","journal-title":"Clin. Transl. Gastroenterol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1462338\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T07:06:45Z","timestamp":1736147205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1462338\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":49,"alternative-id":["10.3389\/fphar.2024.1462338"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1462338","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"article-number":"1462338"}}